뇌졸중 이후의 이상지혈증의 관리

키워드

참고문헌 (79)

1. Benjamin EJ, "Heart disease and stroke statistics-2019 update : a re-port from the American Heart Association", Circulation, 139, pp.e56~e528 (2019)
2. Vangen-Lønne AM, "Declining incidence of ischemic stroke: what is the im-pact of changing risk factors? The Tromsø study 1995 to 2012", Stroke, 48, pp.544~550 (2017)
3. Ganda OP, "Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management", J Am Coll Cardiol, 72, pp.330~343 (2018)
4. Varbo A, "Remnant cholesterol and risk of ischemic stroke in 112, 512 individuals from the general population", Ann Neurol, 85, pp.550~559 (2019)
5. Jepsen AM, "Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease", Clin Chem, 62, pp.593~604 (2016)
6. Su L, "Current management guidelines on hyperlipidemia : the silent killer", J Lipids, 2021, pp.9883352~ (2021)
7. Mach F, "2019 ESC", EAS guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
8. Baigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
9. Kurth T, "Lipid levels and the risk of ischemic stroke in women", Neurology, 68, pp.556~562 (2007)
10. Hindy G, "Role of blood lipids in the development of ischemic stroke and its subtypes : a Mendelian randomization study", Stroke, 49, pp.820~827 (2018)
11. Milionis H, "Statin-based therapy for primary and secondary prevention of ischemic stroke : a meta-analysis and critical overview", Int J Stroke, 15, pp.377~384 (2020)
12. Tramacere I, "Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack : a systematic review and network meta-analysis", BMC Med, 17, pp.67~ (2019)
13. Yebyo HG, "Comparative ef-fectiveness and safety of statins as a class and of specific statins for pri-mary prevention of cardiovascular disease : a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94, 283 participants", Am Heart J, 210, pp.18~28 (2019)
14. Powers WJ, "2018 guidelines for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2018, pp.49, e46~e110
15. Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes", N Engl J Med, 350, pp.1495~1504 (2004)
16. Nichols GA, "Increased cardiovascular risk in hypertriglyceridemic patients with statin-con-trolled LDL cholesterol", J Clin Endocrinol Metab, 103, pp.3019~3027 (2018)
17. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
18. Arnett DK, "2019 ACC", AHA guideline on the primary prevention of cardiovascular disease : a report of the American College of Cardiology, Circulation, pp.2019, 140[DOI]
19. Kernan WN, "Guidelines for the prevention of stroke in pa-tients with stroke and transient ischemic attack : a guideline for health-care professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
20. Meschia JF, "Guidelines for the primary prevention of stroke : a statement for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 3754~3832
21. Wilson PWF, "Systematic review for the 2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
22. Cholesterol Treatment Trialists’ Collaboration, "Efficacy and safety of statin therapy in older people : a meta-analysis of individual partic-ipant data from 28 randomised controlled trials", Lancet, 393, pp.407~415 (2019)
23. Newman CB, "Statin safety and associated adverse events : a scientific state-ment from the American Heart Association", Arterioscler Thromb Vasc Biol, 39, pp.e38~e81 (2019)
24. 이은정, "2018 Guidelines for the management of dyslipidemia", The Korean Journal of Internal Medicine, 34(4), pp.723~771 (2019), 대한내과학회[DOI]
25. Davignon J, "Beneficial cardiovascular pleiotropic effects of statins", Circulation, 109, pp.III39~III43 (2004)
26. Liao JK, "Pleiotropic effects of statins", Annu Rev Pharmacol Toxicol, 45, pp.89~118 (2005)
27. Oesterle A, "Pleiotropic effects of statins on the car-diovascular system", Circ Res, 120, pp.229~243 (2017)
28. Malhotra K, "Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients : a meta-analysis", Atherosclerosis, 282, pp.75~79 (2019)
29. Reeves MJ, "Effect of pretreatment with statins on ischemic stroke outcomes", Stroke, 39, pp.1779~1785 (2008)
30. 허지회, "Effect and Safety of Rosuvastatin in Acute Ischemic Stroke", 대한뇌졸중영문학회지, 18(1), pp.87~95 (2016), 대한뇌졸중학회
31. Montaner J, "Combination of thrombolysis and statins in acute stroke is safe : results of the STARS randomized trial(stroke treat-ment with acute reperfusion and simvastatin)", Stroke, 47, pp.2870~2873 (2016)
32. 정한길, "Early Statins after Intravenous or Endovascular Recanalization Is Beneficial Regardless of Timing, Intensity, and Stroke Mechanism", 대한뇌졸중영문학회지, 19(3), pp.370~372 (2017), 대한뇌졸중학회
33. Kang J, "Early statin use in ischemic stroke patients treated with recanalization therapy : retro-spective observational study", BMC Neurol, 15, pp.122~ (2015)
34. Choi JC, "Effect of pre-stroke statin use on stroke severity and early functional recovery : a retrospective cohort study", BMC Neurol, 15, pp.120~ (2015)
35. Amarenco P, "A comparison of two LDL cholesterol targets after ischemic stroke", N Engl J Med, 382, pp.9~ (2019)
36. Park HK, "Statin ther-apy in acute cardioembolic stroke with no guidance-based indication", Neurology, 94, pp.e1984~e1995 (2020)
37. Mach F, "Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, hae-morrhagic stroke and cataract", Eur Heart J, 39, pp.2526~2539 (2018)
38. Shah RV, "Statins and risk of new-onset diabetes mellitus", Circulation, 126, pp.e282~e284 (2012)
39. Sukhija R, "Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients", J Investig Med, 57, pp.495~499 (2009)
40. Simsek S, "Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes---the CORALL study", Diabet Med, 29, pp.628~631 (2012)
41. Baker WL, "Differing effect of statins on insulin sensitivity in non-diabetics : a systematic review and meta-analysis", Diabetes Res Clin Pract, 87, pp.98~107 (2010)
42. Navarese EP, "Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus", Am J Cardiol, 111, pp.1123~1130 (2013)
43. Cai T, "Associations between statins and adverse events in primary prevention of cardiovascular disease : systematic review with pairwise, network, and dose-response meta-analyses", BMJ, 374, pp.n1537~ (2021)
44. Tomaszewski M, "Statin-in-duced myopathies", Pharmacol Rep, 63, pp.859~866 (2011)
45. Selva-O’Callaghan A, "Statin-induced myal-gia and myositis : an update on pathogenesis and clinical recommend-ations", Expert Rev Clin Immunol, 14, pp.215~224 (2018)
46. Hammersley D, "Ezetimibe : an update on its clinical useful-ness in specific patient groups", Ther Adv Chronic Dis, 8, pp.4~11 (2017)
47. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
48. Bohula EA, "Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT(improved reduction of outcomes : vytorin efficacy international trial)", Circulation, 136, pp.2440~2450 (2017)
49. Chaudhary R, "PCSK9 inhibitors : a new era of lipid lowering therapy", World J Cardiol, 9, pp.76~91 (2017)
50. Burnett JR, "PCSK9-a journey to cardiovascular outcomes", N Engl J Med, 379, pp.2161~2162 (2018)
51. Dullaart RPF, "PCSK9 inhibition to reduce cardiovascular events", N Engl J Med, 376, pp.1790~1791 (2017)
52. Ference BA, "Variation in PCSK9 and HMGCR and risk of car-diovascular disease and diabetes", N Engl J Med, 375, pp.2144~2153 (2016)
53. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
54. Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
55. Amarenco P, "Lipid management in the prevention of stroke : review and updated meta-analysis of statins for stroke prevention", Lancet Neurol, 8, pp.453~463 (2009)
56. Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)
57. Amarenco P, "Results of the stroke prevention by aggressive re-duction in cholesterol levels(SPARCL)trial by stroke subtypes", Stroke, 40, pp.1405~1409 (2009)
58. Goldstein LB, "Hemorrhagic stroke in the stroke prevention by ag-gressive reduction in cholesterol levels study", Neurology, 70, pp.2364~2370 (2008)
59. Flint AC, "Statin ad-herence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation", Stroke, 48, pp.1788~1794 (2017)
60. Qi Z, "Relation of low-den-sity lipoprotein cholesterol to ischemic stroke in patients with non-valvular atrial fibrillation", Am J Cardiol, 119, pp.1224~1228 (2017)
61. Fauchier L, "Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials", J Am Coll Cardiol, 51, pp.828~835 (2008)
62. Fang WT, "The role of statin therapy in the pre-vention of atrial fibrillation : a meta-analysis of randomized controlled trials", Br J Clin Pharmacol, 74, pp.744~756 (2012)
63. Goh SL, "Does preoperative statin therapy prevent postoperative atrial fibrillation in patients undergoing cardiac surgery?", Interact Cardiovasc Thorac Surg, 20, pp.422~428 (2015)
64. Choi KH, "Effect of statin therapy on outcomes of patients with acute ischemic stroke and atrial fibrillation", J Am Heart Assoc, 8, pp.e013941~ (2019)
65. Ornello R, "Distribution and temporal trends from 1993 to 2015 of ischemic stroke subtypes : a systematic review and meta-analysis", Stroke, 49, pp.814~819 (2018)
66. Saver JL, "Cryptogenic stroke", N Engl J Med, 375, pp.e26~ (2016)
67. Amarenco P, "One-year risk of stroke after transient ischemic attack or minor stroke", N Engl J Med, 374, pp.1533~1542 (2016)
68. Amarenco P, "Five-year risk of stroke after TIA or minor ische-mic stroke", N Engl J Med, 378, pp.2182~2190 (2018)
69. Goldstein LB, "Statins after intracerebral hemorrhage : to treat or not to treat", Arch Neurol, 68, pp.565~566 (2011)
70. Collins R, "Effects of cholester-ol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions", Lancet, 363, pp.757~767 (2004)
71. Hackam DG, "Statins and intracerebral hemorrhage : collaborative systematic review and meta-analysis", Circulation, 124, pp.2233~2242 (2011)
72. McKinney JS, "Statin therapy and the risk of intracerebral hemorrhage : a meta-analysis of 31 randomized controlled trials", Stroke, 43, pp.2149~2156 (2012)
73. Westover MB, "Statin use following intracerebral hemorrhage : a decision analysis", Arch Neurol, 68, pp.573~579 (2011)
74. Flint AC, "Effect of statin use during hospitalization for intracerebral hemor-rhage on mortality and discharge disposition", JAMA Neurol, 71, pp.1364~1371 (2014)
75. Tapia-Pérez JH, "Continued statin therapy could improve the outcome after sponta-neous intracerebral hemorrhage", Neurosurg Rev, 36, pp.279~287 (2013)
76. Bailey RD, "Recurrent brain hemor-rhage is more frequent than ischemic stroke after intracranial hemor-rhage", Neurology, 56, pp.773~777 (2001)
77. Casolla B, "Five-year risk of major ischemic and hemorrhagic events after intra-cerebral hemorrhage", Stroke, 50, pp.1100~1107 (2019)
78. Poon MT, "Long-term prognosis after intracerebral haemorrhage : systematic review and meta-analysis", J Neurol Neurosurg Psychiatry, 85, pp.660~667 (2014)
79. Hanger HC, "The risk of recurrent stroke after intracerebral haemorrhage", J Neurol Neurosurg Psychiatry, 78, pp.836~840 (2007)